With $36B From Teva, What Should Allergan Buy Next?
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan has the cash on hand for another transformational transaction, having sold its generics business just three years since Watson’s purchase of Actavis created a generics powerhouse and just months after the purchase of Allergan brought in a brand platform and new name.